Background/Objectives: Young women frequently present with more aggressive breast cancer tumors. This retrospective study analyzed the oncological outcomes of patients under the age of 40 according to the tumor biology. Methods: Group comparisons were performed via the log-rank test. Recurrence and survival rates are presented according to the Kaplan–Meier method. Results: In total, 88 women (mean age 36) were included, but two presented with bilateral cancer, resulting in 90 tumors. Triple-negative carcinoma was most common, with 26.7% (n = 24); 11.1% (n = 10) were luminal A; 23.3% (n = 21) were luminal B HER2-negative; 15.6% (n = 14) were luminal B HER2-positive; and 6.7% (n = 6) were HER2-positive (non-luminal). Moreover, 26.1% (n = 23) of patients experienced recurrence (mean 40 months), with the highest recurrence rate in the HER2-positive (50%) and triple-negative (30.4%) groups. The 3- and 5-year recurrence-free survival rates were 84.9% and 77.3%, and the overall survival rates were 93.1% and 90.3%, respectively. No statistically significant differences in oncological outcomes were observed (p= 0.164). Conclusions: The results show that young women tend to have triple-negative and fast-growing breast carcinomas, with worse overall survival in the triple-negative group. More research is needed on the pathomechanisms of breast cancer development in young women, especially those leading to disease progression and resistance to therapy.
背景/目的：年轻女性常表现为更具侵袭性的乳腺癌肿瘤。本回顾性研究根据肿瘤生物学特征分析了40岁以下患者的肿瘤学结局。方法：组间比较采用对数秩检验。复发率和生存率根据Kaplan-Meier法呈现。结果：共纳入88名女性（平均年龄36岁），其中2例为双侧乳腺癌，共计90个肿瘤。三阴性癌最为常见，占26.7%（n=24）；管腔A型占11.1%（n=10）；管腔B型HER2阴性占23.3%（n=21）；管腔B型HER2阳性占15.6%（n=14）；HER2阳性（非管腔型）占6.7%（n=6）。26.1%（n=23）的患者出现复发（平均40个月），其中HER2阳性组（50%）和三阴性组（30.4%）复发率最高。3年和5年无复发生存率分别为84.9%和77.3%，总生存率分别为93.1%和90.3%。肿瘤学结局未观察到统计学显著差异（p=0.164）。结论：研究结果表明年轻女性倾向于罹患三阴性及快速生长的乳腺癌，其中三阴性组总生存期更差。需要进一步研究年轻女性乳腺癌发展的病理机制，特别是导致疾病进展和治疗抵抗的相关机制。
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology
肿瘤(癌症)患者之家